Our exosome platform technology is at the forefront of the industry. We have taken the lead in overcoming the core preparation challenges of transforming exosomes from scientific research to industrialization, and have achieved large-scale, high-purity, and stable production. Based on innovative carriers, we have efficiently improved the delivery efficiency of nucleic acid drugs and are accelerating the development and clinical translation of the world's first exosome-conjugated drugs.